Allergan Aesthetics, an AbbVie company, has officially launched Skinvive by Juvéderm.
The company hosted a press event on September 30 at St Pancras Renaissance to introduce the injectable to media and specialty guests.
Skinvive is a hyaluronic acid injectable designed to deliver deep hydration in the skin for up to nine months and improvements in skin texture on the face and neck for up to six months after a single treatment. The product is suitable for all Fitzpatrick Skin Types I–VI and is administered using microdroplet injections, designed to restore glow and radiance with minimal downtime, the company explains.
The event featured a panel of television presenter Cat Deeley, podcaster Josh Smith and aesthetic practitioners Dr Sophie Shotter, Dr Glyn Estebanez and Dr Ewoma Ukeleghe, who discussed the role of hydration in skin health and the benefits of the new treatment. Attendees had the opportunity to network and take part in interactive activities.
On the new launch, Dr Estebanez said, “Skinvive takes the hydrating benefits of hyaluronic acid beyond the skin’s surface to deliver deep hydration that transforms the skin from within.”
Djamshid Ghavami, general manager of Allergan Aesthetics UK&I, added, “Skinvive is the latest addition to our growing portfolio of products in the skin quality category and through our investment in research and development, we’ll continue to bring innovations to patients and health care practitioners. The new era for healthy-looking skin starts with Skinvive, changing the skin quality category for good.”
